Improve COVID-19 Response & Healthcare Worker safety through accelerated RNA extraction
Arcis Biotechnology LimitedSuite S07 Techspace OneSci-tech DaresburyDaresbury, Cheshire WA4 4AB United Kingdom
Phone: +44(0)1925 607101
Email: [email protected]
Web: www.arcisbio.com
Rapid RNA Extraction Improves COVID-19 DetectionMedical decisions are time-critical
Current USA FDA-cleared automated platforms have protocol times greater than 1 hour thus delaying rapid qPCR testing.
Arcis chemistry reduces RNA extraction times to 3 min.-> faster clinical decision making
Arcis chemistry inactivates pathogens -> decrease risk for healthcare workers
Arcis chemistry is compatible with liquid handling-> decrease risk for laboratory staff-> support high-throughput testing
Arcis chemistry is compatible with qPCR testing of coronavirus-> ready for use
Arcis protocol consists of 2 reagents:Reagent 1 - Lysis bufferReagent 2 – Wash buffer
Arcis Protocol: Sample to RNA in 3 minutes
Demonstrated compatibility with SARS-CoV-2 qPCR Assay
• Assays testing three other coronavirus subgroupings
• 50μl Sample into 150μl Arcis Reagent 1
• Leave for 1 minute
• Add 10μl to 10μl Reagent 2
• Add 5μl to qRTPCR Assay
Evidence supporting compatibility with other coronavirus assays:UK Hospital confirmed Arcis-compatible qPCR testing (2017*) using protocol below:
3 coronavirus strains tested by UK HospitalSample Genome Test Gold
StandardPrep
Arcis sample Prep*
RESP1 ssRNA 229E CoV 27.52 29.54
RESP2 ssRNA OC43 CoV 28.56 30.43
RESP3 ssRNA NL63 CoV 26.88 29.03
Pilot Study: Hospital Carlos III & CIBERehd (Madrid, Spain)
• Arcis-extracted RNA from Nasopharyngeal swabs from SARS-CoV-2 positive patients was tested. The samples were tested using the CDC-designed SARS-CoV-2 assay.
• Concordant results in 13/15 positive samples when using Arcis compared to the clinically-deployed RNA extraction method (process optimization is ongoing)
* Non-optimised protocol
Other SARS-CoV-2 Screening Sample Types
COVID-19 Sample Types
Arcis-Compatible
Swab ✓
Saliva ✓
Sputum ✓
Blood ✓
Nasopharyngeal AND oropharyngeal swabs are recommended by the CDC for initial diagnostic testing*
Saliva being used by LabCorp in the USA for SARS-CoV-2 testing
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
RNA extracted from saliva (human gene B2M RNA detected)
Protocol:Arcis extractions from saliva ran with the TaqMan Fast virus 1-step master mix90 µl saliva into 150 µl Reagent 1 > 5 ul into 20 µl Reagent 2Reverse transcription step – 5 minuteqPCR step – 35-45 minutes depending on cycle number
Ct’s Mean (SD)
Saliva 29.33,29.51,29.83
29.55 (0.25)
Run Time (minutes) 45
Arcis Protects Healthcare Workers by Pathogen Inactivation
Arcis has shown pathogen inactivation
Control 1 minute Arcis treatment
90µl K.pneumoniae suspension (OD=0.23) + 150µl Reagent 1
• Pathogen inactivation is critical to sample handling & transport
• Arcis reagents inactivate pathogens in 1 minute
• Partner needed for SARS-CoV-2 inactivation validation
Rapid RNA Extraction Improves COVID-19 Response
✓ Arcis chemistry reduces RNA extraction times -> faster clinical decision making
✓ Arcis chemistry inactivates pathogens -> decrease risk for healthcare workers
✓ Arcis chemistry is compatible with qPCR testing of coronavirus
Arcis Biotechnology seeks to collaborate with those working on a COVID-19 diagnostics. With time to result being critical for doctors to know who requires immediate treatment, We are eager to contribute to resolving this global crisis. We are prepared to offer samples, technical support, and collaboration efforts that will lead to faster diagnosis and improved healthcare worker safety.
Please contact Arcis to see how we can support you.
Arcis Biotechnology LimitedSuite S07 Techspace One
Sci-tech DaresburyDaresbury, Cheshire WA4 4AB United Kingdom
Phone: +44(0)1925 607101
Email: [email protected]
Web: www.arcisbio.com
